Targeted Aml1-Eto Neoantigen Cytotoxic T Cells
t(8;21)
BGI, ChinaCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the t(8;21) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Alice Mims | Phase 3 | BBB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
Idarubicine The First Affiliated Hospital of Soochow University | Phase 2 | BBB |
Cyclophosphamide BGI, China | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Targeted Aml1-Eto Neoantigen Cytotoxic T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →